Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5

Karim Fizazi, Robert Jones, Stephane Oudard, Eleni Efstathiou, Fred Saad, Ronald De Wit, Johann De Bono, Felipe Melo Cruz, George Fountzilas, Albertas Ulys, Flavio Carcano, Neeraj Agarwal, David Agus, Joaquim Bellmunt, Daniel P. Petrylak, Shih Yuan Lee, Iain J. Webb, Bindu Tejura, Niels Borgstein, Robert Dreicer

Research output: Contribution to journal › Article › peer-review

121 Scopus citations

Fingerprint

Dive into the research topics of 'Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5'. Together they form a unique fingerprint.

Medicine & Life Sciences